tiprankstipranks
Advertisement
Advertisement

CGTX Stock Latest News

Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial
Company AnnouncementsCognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial
5d ago
8K
CGTX
Analyst Reiterates Buy on Cognition Therapeutics as FDA Clarifies Zervimesine Path; Maintains $3 Price Target
PremiumRatings
Analyst Reiterates Buy on Cognition Therapeutics as FDA Clarifies Zervimesine Path; Maintains $3 Price Target
12d ago
CGTX
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial
PremiumCompany Announcements
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial
19d ago
8K
CGTX
Cognition Therapeutics conducts zervimesine meeting with FDA
PremiumThe Fly
Cognition Therapeutics conducts zervimesine meeting with FDA
19d ago
CGTX
Ram Selvaraju Reiterates Buy on Cognition Amid Clinical Progress and Regulatory Milestones, Keeps 12-Month Price Target Unchanged at $3
PremiumRatings
Ram Selvaraju Reiterates Buy on Cognition Amid Clinical Progress and Regulatory Milestones, Keeps 12-Month Price Target Unchanged at $3
29d ago
CGTX
Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)
PremiumThe FlyCognition Therapeutics reports Q1 EPS (5c), consensus (7c)
1M ago
CGTX
Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications
Premium
Ratings
Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications
2M ago
CGTX
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress
Premium
Company Announcements
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress
2M ago
8K
CGTX
Cognition Therapeutics’ zervimesine shows eficacy in dementia trial
PremiumThe Fly
Cognition Therapeutics’ zervimesine shows eficacy in dementia trial
3M ago
CGTX
Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
PremiumRatings
Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
3M ago
CGTX
Cognition Therapeutics Advances Zervimesine for DLB Psychosis
PremiumCompany Announcements
Cognition Therapeutics Advances Zervimesine for DLB Psychosis
3M ago
8K
CGTX
Cognition Therapeutics announces plans to advance development of zervimesine
PremiumThe Fly
Cognition Therapeutics announces plans to advance development of zervimesine
3M ago
CGTX
Cognition Therapeutics extends duration of EAP for zervimesine
PremiumThe FlyCognition Therapeutics extends duration of EAP for zervimesine
4M ago
CGTX
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial
Premium
Company Announcements
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial
4M ago
8K
CGTX
Cognition Therapeutics completes Type C meeting with FDA for zervimesine
Premium
The Fly
Cognition Therapeutics completes Type C meeting with FDA for zervimesine
4M ago
CGTX
Cognition publishes Phase 2 results on Zervimesine
PremiumThe Fly
Cognition publishes Phase 2 results on Zervimesine
5M ago
CGTX
Cognition Therapeutics Launches New $75M ATM Offering
PremiumCompany Announcements
Cognition Therapeutics Launches New $75M ATM Offering
6M ago
8K
CGTX
Cognition Therapeutics files $300M mixed securities shelf
PremiumThe Fly
Cognition Therapeutics files $300M mixed securities shelf
6M ago
CGTX
Cognition Therapeutics’ Promising Advances in Dementia Treatment Justify Buy Rating
PremiumRatings
Cognition Therapeutics’ Promising Advances in Dementia Treatment Justify Buy Rating
6M ago
CGTX
Cognition reaches full enrollment in expanded access program for CT1812
PremiumThe FlyCognition reaches full enrollment in expanded access program for CT1812
6M ago
CGTX
Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s
Premium
The Fly
Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s
6M ago
CGTX
Cognition Therapeutics price target raisd to $3 from $2 at B. Riley
Premium
The Fly
Cognition Therapeutics price target raisd to $3 from $2 at B. Riley
7M ago
CGTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >